Synthetic LXR ligand inhibits the development of atherosclerosis in mice

By S. Joseph, E. McKilligin, Liming Pei, M. Watson, A. Collins, B. Laffitte, Mingyi Chen, Grace Noh, J. Goodman, G. N. Hagger and 9 more. Proceedings of the National Academy of Sciences of the United States of America, 2002

993 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/ac06168a2a04d772664cdb99bd3474971b191d15

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. I. Tabas
2. P. Tontonoz
3. Christopher K. Glass
4. E. Janssen
5. K. Bornfeldt

In Molecular Biology

1. P. Tontonoz
2. I. Tabas
3. A. Calkin
4. D. Mangelsdorf
5. N. Zelcer
6. Christopher K. Glass
7. S. Bensinger
8. E. Janssen

In Surgery

1. P. Tontonoz
2. I. Tabas
3. A. Calkin
4. S. Bensinger
5. N. Zelcer
6. D. Mangelsdorf
7. Christopher K. Glass
8. P. Edwards

Citations in the corpus

• LXR signaling couples sterol metabolism to proliferation in the acquired immune response (2008, background): “The LXR pathway has been shown to impact inflammatory responses in models of atherosclerosis, contact dermatitis, sepsis, and multiple sclerosis (Hindinger et al., 2006; Joseph et al., 2003; Joseph et al., 2002; Tangirala et al., 2002).”
• Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR (2012, positive): “LXR activation with GW3965 strongly attenuates atherosclerosis in the two most common models — the Apoe -null mouse and the Ldlr -null mous”
• Integration of metabolism and inflammation by lipid-activated nuclear receptors (2008, background): “Systemic administration of synthetic LXR agonists protects against atherosclerosis, effectively blocking atherosclerotic lesion development in susceptible mic”
• Liver X receptor signaling pathways in cardiovascular disease. (2003, background): “pathway might be achieved within the vessel wall (64).”
• The macrophage foam cell as a target for therapeutic intervention (2002, background): “Consistent with this, synthetic LXR and RXR agonists have been shown to reduce atherosclerosis in Ldlr −/− and Apoe −/− mic”
• Macrophage death and defective inflammation resolution in atherosclerosis (2009, background): “In mouse models of atherosclerosis, LXR agonists markedly suppress lesion progression, even after lesions have become established, and deletion of Lxr promotes lesion progressio”